Gyre Therapeutics financials
$7.32−2.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.1M | $22.5M | $37.2M | $30.6M | $29.7M | $22.1M | $27.9M | $25.5M | $25.2M | $27.2M | $27.1M |
| Gross profit | $26.9M | $21.3M | $35.5M | $28.9M | $28.6M | $21.2M | $26.7M | $24.5M | $24.5M | $26.2M | $25.9M |
| Gross margin | 92.4% | 94.6% | 95.3% | 94.7% | 96.1% | 95.9% | 95.8% | 96.2% | 96.9% | 96.4% | 95.4% |
| Operating income | -$14.4M | -$9.4M | $120.0K | $6.9M | -$2.2M | $2.3M | $663.0K | $4.2M | $3.3M | $8.1M | -$88.3M |
| Net income | -$11.7M | -$8.7M | -$1.7M | $3.6M | -$2.0M | $2.7M | -$99.0K | $1.1M | $3.5M | $7.5M | -$101.0M |
| Net margin | −40.1% | −38.6% | −4.6% | 11.8% | −6.9% | 12.2% | −0.4% | 4.4% | 14.0% | 27.7% | −372.1% |
| Diluted EPS | $-0.12 | $-0.10 | $-0.01 | $0.03 | $-0.03 | $0.03 | $0.00 | $0.01 | $0.01 | $0.03 | $-3.80 |
| EBITDA | -$12.9M | -$8.7M | $815.0K | $7.6M | -$1.2M | $2.8M | $1.2M | $4.7M | $3.5M | $8.5M | -$88.0M |
| Operating cash flow | -$16.7M | $3.2M | -$5.6M | $4.7M | -$7.5M | -$129.0K | -$2.8M | $1.7M | -$5.5M | $2.9M | $3.4M |
| Free cash flow | -$17.0M | $3.0M | -$5.8M | $4.0M | -$7.8M | -$251.0K | -$2.8M | $1.0M | -$6.9M | $2.7M | $1.0M |
| Diluted shares | 100.6M | 91.3M | 117.6M | 104.0M | 89.2M | 102.0M | 101.7M | 102.6M | 102.2M | 102.6M | 26.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.3M | $37.5M | $49.2M | $40.4M | $36.5M | $15.0M |
| Short-term investments | $31.5M | $12.3M | $43.4M | $19.6M | $17.9M | $14.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $199.3M | $162.0M | $219.8M | $159.4M | $152.6M | $129.8M |
| Total liabilities | $34.3M | $25.0M | $31.4M | $22.0M | $23.2M | $25.5M |
| Shareholders' equity | $142.5M | $137.0M | $59.5M | $137.4M | $129.4M | $104.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology